Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Klaria Pharma Q3 2023 - Take-off is on the horizon

Klaria Pharma Holding

Redeye leaves a research update following Klaria Pharma’s Q3 2023 report. As we near the end of 2023, we argue that the company draws closer to the many potential inflection points in store for the upcoming year. While Klaria Pharma’s short-term finances are a remaining hurdle, we anticipate a rights issue around year-end. However, we do not dismiss the possibility of a non-dilutive capital injection through an upcoming milestone payment or a potential licensing agreement with its sumatriptan alginate film.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Klaria Pharma Q3 2023 - Take-off is on the horizon

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.